Galapagos NV (NASDAQ:GLPG) is Stonepine Capital Management LLC's 4th Largest Position

Stonepine Capital Management LLC decreased its position in Galapagos NV (NASDAQ:GLPG - Free Report) by 58.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,000 shares of the biotechnology company's stock after selling 278,659 shares during the quarter. Galapagos accounts for 4.4% of Stonepine Capital Management LLC's portfolio, making the stock its 4th biggest holding. Stonepine Capital Management LLC owned approximately 0.30% of Galapagos worth $5,500,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. R Squared Ltd bought a new stake in Galapagos during the fourth quarter worth approximately $26,000. American Century Companies Inc. boosted its holdings in shares of Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after purchasing an additional 1,431 shares during the period. QRG Capital Management Inc. increased its position in shares of Galapagos by 21.7% during the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 1,866 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in Galapagos by 19.6% during the 4th quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company's stock valued at $617,000 after buying an additional 3,684 shares during the period. 32.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on GLPG shares. Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and dropped their price objective for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Wall Street Zen lowered shares of Galapagos from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Finally, Barclays restated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Five equities research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $25.33.

Galapagos Stock Down 0.1%

NASDAQ:GLPG traded down $0.02 during mid-day trading on Friday, reaching $28.76. The company's stock had a trading volume of 90,590 shares, compared to its average volume of 238,607. Galapagos NV has a 1 year low of $22.36 and a 1 year high of $31.23. The stock has a fifty day moving average of $25.66 and a 200-day moving average of $25.93.

Galapagos (NASDAQ:GLPG - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The company had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. As a group, research analysts anticipate that Galapagos NV will post -1.6 EPS for the current fiscal year.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.